Lilly’s donanemab could bring new hope to Alzheimer’s patients in Australia following lecanemab rejection: GlobalData Read more
Missing the obvious in technology transfer. Focusing on coating process. | 19th November 2024 Read more
NICE rejects second Alzheimer’s drug but opportunity remains for decision change: GlobalData Read more